Drug intelligence / Profile preview

BPM-RSV-002

Development stage: Preclinical
Lead developer: Baiya Phytopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BPM-RSV-002 is a neutralizing monoclonal antibody being developed by Baiya Phytopharm for the prevention and treatment of Respiratory Syncytial Virus (RSV) infection. It specifically targets the RSV fusion (F) protein, a critical component that mediates the fusion of the viral envelope with the host cell membrane, thereby allowing viral entry. By binding to the F protein, BPM-RSV-002 neutralizes the virus and prevents infection of host cells. The candidate is produced using Baiya Phytopharm's proprietary plant-based protein expression platform (BaiyaPharming) and is currently in preclinical development.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on BPM-RSV-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM-RSV-002.

Explore the full profile